Alfa Cytology
Preclinical oncology contract research organization providing discovery-to-IND services including in vitro and in vivo efficacy models, immune-oncology evaluation, small-molecule and biologics discovery, cell and gene therapy and oncolytic viral development, multi-omics biomarker analysis, preclinical imaging, and PK/ADME/toxicology testing.
Industries
Nr. of Employees
medium (51-250)
Services
Design and execution of in vivo efficacy studies using xenograft, syngeneic, PDX and humanized models.
Antigen generation, antibody selection, engineering, optimization and analytical characterization including ADC and multispecific formats.
Vector and virus construction, engineering and preclinical validation workflows for oncolytic and gene-delivery platforms.
HTS implementation and hit-to-lead workflows including computational screening and medicinal chemistry optimization for small-molecule development.
Integrated genomics, transcriptomics, proteomics, single-cell and spatial omics plus exosome profiling to identify and validate diagnostic and predictive biomarkers.
MRI, PET and CT imaging combined with advanced image reconstruction and ML analysis for tumor and microenvironment assessment.
Design and execution of in vivo efficacy studies using xenograft, syngeneic, PDX and humanized models.
Antigen generation, antibody selection, engineering, optimization and analytical characterization including ADC and multispecific formats.
Vector and virus construction, engineering and preclinical validation workflows for oncolytic and gene-delivery platforms.
HTS implementation and hit-to-lead workflows including computational screening and medicinal chemistry optimization for small-molecule development.
Integrated genomics, transcriptomics, proteomics, single-cell and spatial omics plus exosome profiling to identify and validate diagnostic and predictive biomarkers.
MRI, PET and CT imaging combined with advanced image reconstruction and ML analysis for tumor and microenvironment assessment.
Expertise Areas
- Preclinical oncology research and CRO program delivery
- Cancer model development (PDX, GEMM, humanized, syngeneic)
- Immuno-oncology assay development and combination therapy evaluation
- Small-molecule discovery, high-throughput screening and lead optimization
Key Technologies
- Patient-derived xenograft (PDX) models
- Humanized rodent models
- Genetically engineered models (GEMMs)
- High-throughput screening (HTS)